The AFSSAPS, France's safety regulator for health products, has suspended the sale of products containing fluoride salts as a treatment for osteoporosis.
The agency said that its most recent assessment of the efficacy of sodium fluoride compared to its potential risks showed that it performed unfavourably compared to alternative treatments such as biphosphonates, especially given the potential long-term risks of fluorosis.
The AFSSAPS has therefore recalled from sale all speciality products containing fluoride salts: Architex from Cooper, Osteofluor 25mg pills from Lipha Santé and Fluocalcic from Yamanouchi Pharma.